{"id":"NCT00790400","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2011-06","completion":"2015-11","firstPosted":"2008-11-13","resultsPosted":"2012-08-28","lastUpdate":"2017-02-17"},"enrollment":118,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tuberous Sclerosis Complex (TSC)","Lymphangioleiomyomatosis (LAM)"],"interventions":[{"type":"DRUG","name":"Everolimus (RAD001)","otherNames":["RAD001"]},{"type":"DRUG","name":"Everolimus Placebo","otherNames":[]}],"arms":[{"label":"Everolimus","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.","primaryOutcome":{"measure":"Angiomyolipoma Response Rate as Per Central Radiology Review","timeFrame":"From date of randomization until the earliest date of first documented AML progression, date of further anti-AML medication (including open-label Everolimus)/surgery or up to 5.7 years","effectByArm":[{"arm":"Everolimus Randomized (Core Period)","deltaMin":41.8,"sd":null},{"arm":"Placebo Randomized (Core Period)","deltaMin":0,"sd":null},{"arm":"Everolimus (Core and/or Extension Period)","deltaMin":58,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":22},"locations":{"siteCount":25,"countries":["United States","Canada","France","Germany","Italy","Japan","Netherlands","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":["23312829","30192751","30053159","29023494","26156073"],"seeAlso":["http://www.novartisclinicaltrials.com/webapp/portals/EXISTClinicalTrials/page.do"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":79},"commonTop":["Nasopharyngitis","Stomatitis","Headache","Hypercholesterolaemia","Urinary tract infection"]}}